Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Experimental RNAi02:15

Experimental RNAi

6.8K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.8K
MicroRNAs01:22

MicroRNAs

3.4K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.4K
MicroRNAs01:22

MicroRNAs

23.1K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

9.4K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extruded biodegradable Zn-5Cu alloys with integrated osteoimmunomodulatory, antibacterial, and anti-osteolytic properties for patellar fracture suture repair.

Acta biomaterialia·2026
Same author

Association between frailty status and osteomyelitis: A nested case-control study.

PloS one·2026
Same author

Diabetes and the risk of delayed union or non-union of fractures: evidence from a systematic review and meta-analysis.

Scientific reports·2026
Same author

Joint risk factor within target range and hazard of premature mortality in people with obesity.

Scientific reports·2026
Same author

A novel design conception of foot orthoses promotes normal walking in patients with pronated feet.

Journal of neuroengineering and rehabilitation·2026
Same author

Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial.

Lancet (London, England)·2026

Related Experiment Video

Updated: Nov 17, 2025

Author Spotlight: RNA FISH for Locating lncRNA-SNHG6 in Osteosarcoma Cells
05:27

Author Spotlight: RNA FISH for Locating lncRNA-SNHG6 in Osteosarcoma Cells

Published on: June 16, 2023

2.0K

Noncoding RNAs in osteosarcoma: Implications for drug resistance.

Zhengjun Lin1, Xubin Xie2, Shiyao Lu2

  • 1Department of Orthopedics, The Second Xiangya Hospital of Central South University, 139 Renmin Road, Changsha, 410011, Hunan, People's Republic of China; Xiangya School of Medicine, Central South University, Changsha, 410013, Hunan Province, China.

Cancer Letters
|February 15, 2021
PubMed
Summary

Noncoding RNAs (ncRNAs) are key players in osteosarcoma drug resistance, hindering treatment effectiveness. Targeting these ncRNAs offers a promising strategy to overcome multi-drug resistance (MDR) and improve patient outcomes.

Keywords:
Circular RNADrug resistanceLong noncoding RNAMicroRNAOsteosarcoma

More Related Videos

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

4.0K
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

14.0K

Related Experiment Videos

Last Updated: Nov 17, 2025

Author Spotlight: RNA FISH for Locating lncRNA-SNHG6 in Osteosarcoma Cells
05:27

Author Spotlight: RNA FISH for Locating lncRNA-SNHG6 in Osteosarcoma Cells

Published on: June 16, 2023

2.0K
A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

4.0K
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

14.0K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Osteosarcoma is the most common bone cancer in children and adolescents.
  • Current treatments for osteosarcoma have plateaued in improving survival rates.
  • Multi-drug resistance (MDR) is a major challenge in osteosarcoma chemotherapy.

Purpose of the Study:

  • To review the roles of noncoding RNAs (ncRNAs) in osteosarcoma chemoresistance.
  • To elucidate the molecular mechanisms by which ncRNAs regulate drug resistance.
  • To discuss ncRNAs as potential biomarkers and therapeutic targets for osteosarcoma.

Main Methods:

  • Systematic review of existing literature on ncRNAs and osteosarcoma drug resistance.
  • Analysis of molecular mechanisms underlying ncRNA-mediated chemoresistance.
  • Discussion of therapeutic implications and biomarker potential of ncRNAs.

Main Results:

  • Noncoding RNAs (ncRNAs), including miRNAs, lncRNAs, and circRNAs, are frequently dysregulated in osteosarcoma.
  • These ncRNAs significantly influence osteosarcoma cell sensitivity to chemotherapy drugs.
  • Various molecular pathways are modulated by ncRNAs to induce or overcome drug resistance.

Conclusions:

  • Noncoding RNAs play critical roles in the development and progression of osteosarcoma chemoresistance.
  • Targeting specific ncRNAs presents a novel therapeutic avenue to overcome MDR in osteosarcoma.
  • ncRNAs hold promise as diagnostic and prognostic biomarkers for osteosarcoma patients.